Ardsley Advisory Partners acquired a new stake in Boston Scientific Co. (NYSE:BSX) in the fourth quarter, Holdings Channel reports. The firm acquired 20,000 shares of the medical equipment provider’s stock, valued at approximately $496,000.
Several other institutional investors have also bought and sold shares of the company. Teachers Retirement System of The State of Kentucky increased its position in shares of Boston Scientific by 74.3% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 911,657 shares of the medical equipment provider’s stock valued at $22,600,000 after buying an additional 388,577 shares in the last quarter. HBK Investments L P acquired a new stake in shares of Boston Scientific in the fourth quarter worth approximately $2,516,000. Two Sigma Investments LP boosted its stake in shares of Boston Scientific by 79.2% in the fourth quarter. Two Sigma Investments LP now owns 3,702,539 shares of the medical equipment provider’s stock worth $91,786,000 after acquiring an additional 1,635,881 shares during the last quarter. Two Sigma Advisers LP boosted its stake in shares of Boston Scientific by 59.0% in the fourth quarter. Two Sigma Advisers LP now owns 7,426,814 shares of the medical equipment provider’s stock worth $184,111,000 after acquiring an additional 2,756,504 shares during the last quarter. Finally, Robecosam AG boosted its stake in shares of Boston Scientific by 2.0% in the fourth quarter. Robecosam AG now owns 493,804 shares of the medical equipment provider’s stock worth $12,439,000 after acquiring an additional 9,903 shares during the last quarter. Institutional investors and hedge funds own 91.85% of the company’s stock.
In other news, EVP Michael P. Phalen sold 15,835 shares of the company’s stock in a transaction on Friday, December 29th. The stock was sold at an average price of $25.25, for a total value of $399,833.75. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP David A. Pierce sold 5,152 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $27.00, for a total value of $139,104.00. Following the completion of the transaction, the senior vice president now directly owns 38,116 shares in the company, valued at approximately $1,029,132. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,276 shares of company stock worth $4,592,464. Corporate insiders own 0.74% of the company’s stock.
A number of analysts have recently issued reports on BSX shares. Royal Bank of Canada reaffirmed a “top pick” rating and issued a $32.00 price target on shares of Boston Scientific in a research note on Monday, March 5th. Canaccord Genuity lowered their price target on Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, November 29th. TheStreet raised Boston Scientific from a “c+” rating to a “b” rating in a research note on Thursday, January 18th. Zacks Investment Research lowered Boston Scientific from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, ValuEngine lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $31.06.
Boston Scientific Co. (BSX) opened at $28.54 on Tuesday. The firm has a market capitalization of $39,240.00, a price-to-earnings ratio of 40.77, a price-to-earnings-growth ratio of 2.06 and a beta of 0.82. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.49 and a current ratio of 0.68. Boston Scientific Co. has a 12 month low of $24.02 and a 12 month high of $29.93.
Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.34. The company had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.39 billion. Boston Scientific had a return on equity of 24.27% and a net margin of 1.15%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 earnings per share. equities analysts forecast that Boston Scientific Co. will post 1.37 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/03/13/20000-shares-in-boston-scientific-co-bsx-purchased-by-ardsley-advisory-partners.html.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.